Skip to main content
Premium Trial:

Request an Annual Quote

Stilla Technologies Raises €20M in Series B Round

NEW YORK – Stilla Technologies announced on Tuesday that it has raised €20 million ($22 million) in a Series B funding round.

The round includes a new investor, China-based TUS-Holdings. Stilla will use the funds to support development of a next-generation digital PCR platform and to expand in Asia.

In addition to TUS-Holding, funding in the round came from the firm's existing investors including Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement, and Idinvest Partners.

Paris, France-based Stilla will use the funds to develop a next-generation solution featuring superior analytical performance, including six-color detection capabilities, Rémi Dangla, cofounder and CEO of Stilla Technologies, said in a statement.

Furthermore, "Our future focus will be to apply our state-of-the-art technology to clinical diagnostics, to the benefit of patients," Dangla added. And, by bringing TUS-Holdings on board, "We also look to rapidly expand our activities in China and throughout Asia, while maintaining strong growth of the business in Europe and the United States."

Daniel Wang, CEO of TUS-Holding's European subsidiary Tuspark Europe, was also appointed a member of Stilla's board of directors.

"TUS will spare no effort to facilitate Stilla's growth, including by granting the company access to our innovation ecosystem and network," Wang said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.